We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients (GERICO10)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01254513
Recruitment Status : Unknown
Verified January 2013 by UNICANCER.
Recruitment status was:  Recruiting
First Posted : December 6, 2010
Last Update Posted : January 30, 2013
Information provided by (Responsible Party):

Brief Summary:

The objective of this study is to evaluate the feasibility of two different chemotherapy protocols with adjusted doses for patients aged 75 and over who often have medical problems other than prostate cancer. Patient will receive Docetaxel either every 3 weeks or weekly. In both cases, chemotherapy is combined with prednisone. The protocol will be considered feasible when patient will receive 6 cycles of chemotherapy (1 cycle = 3 weeks).

Additionally to this primary objective, efficacy will also be evaluated for both protocols as well as tolerance to treatment, quality of life and evolution of geriatric data.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Docetaxel every 3 weeks + Prednisone Drug: Docetaxel weekly+ Prednisone Phase 2

Detailed Description:

Standard management of castration-resistant metastatic prostate cancer is represented by chemotherapy with Docetaxel 75 mg/m² every 3 weeks combined with Prednisone since a symptomatic and overall survival benefit was demonstrated.

Although this benefit is independent of age in the study by Tannock (cut-off:69), it does not seem possible to extrapolate these results, obtained in a selected population, to the majority of patients we encounter in daily practice, >= 75 years old and / or unfit.

Retrospective studies have shown that chemotherapy was feasible, at standard or adapted doses in an unselected elderly population with good results in terms of tolerance and efficacy over symptoms.

Our study aims to evaluate prospectively the feasibility of a chemotherapy with Docetaxel/Prednisone administered every 3 weeks (60 mg / m² at D1C1 then 70 mg / m² at D1 for subsequent cycles if tolerance is good) or weekly (35mg / m² at D1 and D8 with Day 1 = Day 21) to patients >= 75 years old, evaluated by comprehensive geriatric assessment, belonging to group 2 "vulnerable" or to group 3 "frail" of the classification proposed by the International Society of Geriatric Oncology (SIOG).

Feasibility is defined as the possibility for a patient to receive 6 cycles of chemotherapy without withdrawal. Reasons for study withdrawal were defined by the GERICO Group and are the followings:

  • stop or delay of chemotherapy > 2 weeks
  • Necessity to reduce the dose of chemotherapy > 25 %
  • febrile neutropenia or non-haematological grade 3 toxicity (except alopecia) according to NCI-CTCAE V4.0.
  • Geriatric criterion (Activity of Daily Living (ADL) decrease >= 2 points)

The statistical methodology used is a double randomized phase II after stratification according to the SIOG criteria, based on a Simon Optimum plan.

A pharmacokinetic / pharmacodynamic study is associated to our project, based on a method of population pharmacokinetic. The aim is to highlight predictors of the haematological tolerance of this chemotherapy by evaluating clinical, geriatric and biological parameters.

The results of this study will support the terms of prescription of chemotherapy, in patients aged 75 and over, classified as "vulnerable" or "frail" regarding SIOG criteria, with defined geriatric assessment.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 144 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Study Evaluating the Feasibility of a Chemotherapy With Docetaxel-Prednisone in a Weekly Schedule or Every 3 Weeks, for Castration-resistant Metastatic Prostate Cancer Elderly Patients (>=75), "Vulnerable" or "Frail" , as Defined by the Criteria of the International Society of Geriatric Oncology (SIOG)
Study Start Date : November 2010
Estimated Primary Completion Date : November 2013
Estimated Study Completion Date : November 2016

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Arm A - Docetaxel every 3 weeks + Prednisone
  • Docetaxel: 60 mg/m²/day at C1 then 70 mg/m²/day for subsequent cycles every 3 weeks
  • Prednisone 10 mg/day continuously
Drug: Docetaxel every 3 weeks + Prednisone
  • Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks
  • Prednisone 10 mg/day continuously
Other Name: TAXOTERE
Drug: Docetaxel weekly+ Prednisone
  • Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)
  • Prednisone 10 mg/day continuously
Other Name: TAXOTERE
Experimental: Arm B - Docetaxel weekly + Prednisone
  • Docetaxel weekly 35 mg/m²/day on day 1 and day 8 of each cycle (J1 = J21)
  • Prednisone 10 mg/day continuously
Drug: Docetaxel weekly+ Prednisone
  • Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)
  • Prednisone 10 mg/day continuously
Other Name: TAXOTERE

Primary Outcome Measures :
  1. Feasibility of 2 different protocols of Docetaxel chemotherapy [ Time Frame: Up to 18 weeks (6 cycles of chemotherapy) ]

    Main criteria is the rate of patients receiving 6 cycles of treatment without experiencing any of the following criteria:

    • Stop or delay of chemotherapy > 2 weeks
    • Necessity to reduce the dose of chemotherapy > 25 %
    • Febrile neutropenia or non-haematological grade 3 toxicity (except alopecia)according to NCI-CTCAE V4.0
    • Geriatric criterion ( ADL decrease >= 2 points)

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: From randomization until death for any cause or last follow-up news (censored data) ]
    Overall Survival is defined as the time from randomization until death for any cause or last follow-up news (censored data).

  2. Geriatric evaluation [ Time Frame: At baseline, D1 of Cycle 1 and Cycle 4, at the end of treatment and at follow-up visits ]

    The impact of the chemotherapy will be evaluated on Comprehensive Geriatric Assessment :

    • Test de screening G8
    • Cumulative Illness Rating Scale(CIRSG)
    • Folstein Mini Mental State (MMS)
    • Activity of Daily Living (ADL)
    • Instrumental Activity of Daily Living (IADL)
    • Geriatric Depression Scale (GDS)
    • Mini Nutritionnal Assessment (MNA)

  3. Number of patients with Adverse Events [ Time Frame: At baseline, D1 of each cycle , at the end of treatment and at the follow-up visits ]
    Tolerance and safety will be assessed through recording of adverse events using NCI-CTCAE toxicity classification V4.0.

  4. Quality of Life [ Time Frame: At baseline, D1 of the Cycle 4, at the end of the treatment and at the follow-up visits ]
    The impact of the chemotherapy is evaluated on the European Organisation for Research and Treatment of Cancer (EORTC) Quality Of Life - Questionnaire - QLQ-C30

  5. Vital signs measurement [ Time Frame: At baseline, D1 of each cycle , at the end of treatment and at the follow-up visits ]
    Tolerance and safety will be assessed through vital signs measurement.

  6. Prostate-specific antigen (PSA) measurements [ Time Frame: At baseline, D1 of each cycle , at the end of treatment and at the follow-up visits ]
    Efficacy will be assessed through monitoring PSA values

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   75 Years and older   (Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age >= 75
  • Histologically proven prostate adenocarcinoma
  • Metastatic disease, not pre-treated with chemotherapy refractory to castration
  • Hormone refractory prostate cancer is defined as follows:

    • Patients with documented testosterone castration (<0.50 ng / ml)
    • Patient who received prior hormonal therapy (either orchidectomy or Luteinizing hormone-releasing hormone (LHRH) agonist alone or combined with an anti-androgen)
    • Patients should continue primary androgen suppression by LHRH agonist (in case of non-surgical castration)
    • For patients treated with anti-androgens prior to inclusion, a wash-out period is required (4 weeks for flutamide and nilutamide, 6 weeks for other products) as well as measured progression after anti-androgen discontinuation.
  • Progressive disease under hormonotherapy, with progression defined by

Increase of PSA level (two consecutive increases of PSA compared to baseline with a minimum of one week between both measurements)

OR emergence of a new lesion

OR measurable progressive disease (increase of a previous measurable lesion >= 25% in cross section)

OR progressive bone metastases (defined only by the appearance of a new lesion on bone scan)

OR progressive symptoms (defined as cancer pain Grade 2 according to the NCI-CTC V4.0, despite level 2 analgesics intake).

  • Patients of Groups 2 and 3 [ "vulnerable" and "frail"] of SIOG classification
  • WHO Performance Status (PS) >= 3
  • PSA >= 5 ng / ml
  • Neutrophils >= 2.109 /L
  • Platelets >= 100.109/L
  • Haemoglobin ≥ 9 g/dl
  • Bilirubin and SGOT / SGPT <1.5 x ULN (<= 2.5 x ULN if hepatic metastasis)
  • creatinine <= 2.5 x ULN
  • In case of previous palliative or analgesic radiotherapy, a minimum of 14 days must have elapsed between end of radiotherapy and inclusion into the study
  • Previous treatment with bisphosphonates should be continued without change during the study treatment and can not be initiated either within 28 days prior to study entry or during the study
  • Signed informed consent by patients, according to local regulations

Exclusion Criteria:

  • "healthy" or "terminal illness" Groups according to the recommendations of International Society of Geriatric Oncology (SIOG)
  • Concomitant or previous malignancy within 5 years prior the study (except basal or squamous in situ cell skin carcinoma)
  • Presence of brain metastasis symptoms
  • Prior treatment by intravenous radiopharmaceutical agent (e.g. Strontium 89, Samarium lexidronam) within 2 months before study entry
  • Initiation of a bisphosphonate therapy within 28 days prior to randomisation
  • Any concomitant anticancer treatment (radiotherapy, radiopharmaceutical agent, chemotherapy)
  • Patients with uncontrolled infection
  • Patients with peripheral neuropathy of grade> 1
  • Patients medically unstable (e.g. unstable diabetes, uncontrolled hypertension or decompensated heart failure or myocardial infarct within 3 months)
  • Gastro duodenal active ulcer
  • Hypersensitivity to study drugs
  • Treatment with any experimental drug within 30 days prior to or during the study
  • Psychological, familial, sociological or geographical location conditions which do not allow medical monitoring and compliance with study protocol.
  • Patients protected by the law or patients placed under protective supervision of adults

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01254513

Contact: Christine Orsini + c-orsini@unicancer.fr

Clinique Claude Bernard Recruiting
Albi, France, 81000
Contact: Philippe HOUYAU, Dr       philippe.houyau@claude-bernard-albi.com   
Principal Investigator: Philippe HOUYAU         
CHI Annemasse-Bonneville Not yet recruiting
Ambilly, France, 74100
Contact: Carol ALLIOT    04 50 87 40 37    calliot@chi-annemasse-bonneville.fr   
Principal Investigator: Carol ALLIOT         
Centre Paul Papin Recruiting
Angers, France, 49933
Contact: Sophie ABADIE       sophie.abadie-lacourtoisie@ico.unicancer.fr   
Principal Investigator: Sophie ABADIE         
CH de Blois Not yet recruiting
Blois, France, 41016
Contact: Charles-Emmanuel GEFFROY    02 54 55 63 95    cegeffroy@ch-blois.fr   
Principal Investigator: Charles-Emmanuel GEFFROY         
Institut Bergonie Recruiting
Bordeaux Cedex, France, 33076
Contact: Nadine HOUEDE, Dr       houede@bergonie.org   
Principal Investigator: Nadine HOUEDE         
Centre Francois Baclesse Recruiting
Caen, France, 14076
Contact: Emmanuel SEVIN, Dr       e.sevin@baclesse.fr   
Principal Investigator: Emmanuel SEVIN         
CH Intercommunal Recruiting
Castres, France, 81108
Contact: Corinne SARDA       c-sarda@chic-cm.fr   
Principal Investigator: Corinne SARDA         
Centre Hospitalier de Chambery Not yet recruiting
Chambery, France, 73011
Contact: Armelle DUFRESNES, Dr       a.dufresne@hotmail.com   
Principal Investigator: Armelle DUFRESNES         
Centre Jean Perrin Recruiting
Clermont-ferrand, France, 63011
Contact: Hakim MAHAMMEDI    04 73 27 80 80    hakim.mahammedi@cjp.fr   
Principal Investigator: Hakim MAHAMMEDI         
Clinique Sainte Marguerite Recruiting
Hyeres, France, 83400
Contact: Jean-François BERDAH         
Principal Investigator: Jean-françois BERDAH         
Chd Vendee Recruiting
La Roche Sur Yon, France, 85925
Contact: Frank PRIOU, Dr       frank.priou@chd-vendee.fr   
Principal Investigator: Frank Priou         
Clinique Hartmann Recruiting
Levallois-perret, France, 92300
Contact: Jean-Michel VANNETZEL, Dr       jmvannetzel@i-o-h.org   
Principal Investigator: Jean-Michel VANNETZEL         
Centre Oscar Lambret Not yet recruiting
Lille, France, 59020
Contact: Armelle CATY         
Principal Investigator: Armelle Caty         
Hôpital Saint Vincent de Paul Not yet recruiting
Lille, France, 59020
Contact: Christophe DESAUW       desauw.christophe@ghicl.net   
Principal Investigator: Christophe DESAUW         
Centre Leon Berard Recruiting
Lyon, France, 69373
Contact: Aude FLECHON         
Principal Investigator: Aude FLECHON         
Institut Paoli Calmettes Recruiting
Marseille, France, 13273
Contact: Gwenaëlle GRAVIS-MESCAM, Dr       gravisg@marseille.fnclcc.fr   
Principal Investigator: Gwenaëlle GRAVIS-MESCAM         
CHU Nimes Recruiting
Nimes, France, 30000
Contact: Mounira EL DEMERY    04 66 68 43 77    mounia.eldemery@chu-nimes.fr   
Principal Investigator: Mounira EL DEMERY         
Chr Orleans Recruiting
Orleans, France, 45100
Contact: Jérôme MEUNIER, Dr       jerome.meunier@chr-orleans.fr   
Principal Investigator: Jérôme Meunier         
Institut Curie/Claudius Regaud Not yet recruiting
Paris, France, 75005
Contact: Philippe BEUZEBOC         
Principal Investigator: Philippe BEUZEBOC         
Centre Hospitalier Lyon Sud Recruiting
Pierre-benite, France
Principal Investigator: Claire FALANDRY         
Centre Hospitalier de La Region D'Annecy Recruiting
Pringy Cedex, France, 74374
Contact: Laetitia STEFANI, Dr       lstefani@ch-annecy.fr   
Principal Investigator: Laetitia STEFANI         
Polyclinique Francheville Recruiting
Périgueux, France, 24000
Contact: Laurent CANY    05 53 02 13 32    l.cany@oncoradio24.com   
Principal Investigator: Laurent CANY         
Institut Curie - Centre Rene Huguenin Not yet recruiting
Saint-cloud, France, 92210
Contact: Alain GOUPIL, Dr       alain.goupil@curie.net   
Principal Investigator: Alain GOUPIL         
Ico - Centre Rene Gauducheau Recruiting
Saint-herblain Cedex, France, 44885
Contact: Emmanuelle BOMPAS, Dr       e-bompas@nantes.fnclcc.fr   
Principal Investigator: Emmanuelle BOMPAS         
CH de Senlis Recruiting
Senlis, France, 60300
Contact: Elisabeth CAROLA       elisabeth.carola@ch-senlis.fr   
Principal Investigator: Elisabeth CAROLA         
Centre Paul Strauss Not yet recruiting
Strasbourg, France, 67065
Contact: Christian BOREL, Dr       cborel@strasbourg.fnclcc.fr   
Principal Investigator: Christian Borel         
Hôpitaux du Léman Not yet recruiting
Thonon-les-bains, France, 74200
Contact: Khoutir MAHOUR BACHA       k-mahour@ch-hopitauxduleman.fr   
Principal Investigator: Khoutir MAHOUR BACHA         
Institut Claudius Regaud Recruiting
Toulouse, France, 31052
Contact: Loïc MOUREY    05 61 42 41 74    loic.mourey@claudiusregaud.fr   
Principal Investigator: Loic Mourey         
Polyclinique Du Parc Recruiting
Toulouse, France, 31078
Contact: Igor LATORZEFF, Dr       i.latorzeff@clinique-pasteur.com   
Principal Investigator: Igor LATORZEFF         
Clinique Saint Jean du Languedoc Not yet recruiting
Toulouse, France, 31400
Contact: Etienne SUC       esucsjl@club-internet.fr   
Principal Investigator: Etienne SUC         
Clinique Pasteur Recruiting
Toulouse, France
Principal Investigator: Igor LATORZEFF         
Sponsors and Collaborators
Principal Investigator: Loic Mourey Institut Claudius Regaud

Responsible Party: UNICANCER
ClinicalTrials.gov Identifier: NCT01254513     History of Changes
Other Study ID Numbers: GERICO10/0910 (GetugP03)
First Posted: December 6, 2010    Key Record Dates
Last Update Posted: January 30, 2013
Last Verified: January 2013

Keywords provided by UNICANCER:
Metastatic Prostate cancer
Elderly patients
Vulnerable and Frail (SIOG classification)

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal